Business
CorMedix Therapeutics Announces Leadership and Board Updates
BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced an addition to its executive leadership team and updates to its Board of Directors. CorMedix CEO Joseph Todisco has signed an extended employment contract, reaffirming his long-term commitment to the organization. In addition to his role as CEO, Mr. T
About this update from Cormedix Inc.
[{"type":"image","alt":"CorMedix, Inc.","displaySize":"","headline":null,"caption":"CorMedix, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":202,"height":45,"url":"https://media.zenfs.com/en/globenewswire.com/51f441ac293f999ee517fc590cd80730"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/c5OvX2_NmCuvbl9BhVk81Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/51f441ac293f999ee517fc590cd80730","width":202,"height":45}},"lazy":false},{"type":"text","content":"BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced an addition to its executive leadership team and updates to its Board of Directors. CorMedix CEO Joseph Todisco has signed an extended employment contract, reaffirming his long-term commitment to the organization. In addition to his role as CEO, Mr. Todisco will also assume the role of Chairman of the Board of Directors, succeeding Myron Kaplan. Mr. Kaplan will transition into a newly created board position of Lead Independent Director.","length":689,"tagName":"p"},{"type":"text","content":"“Under the leadership of Mr. Todisco, CorMedix has evolved from a single product, development stage company into a multi-product, diversified commercial operation with positive cashflow and a strong pipeline,” says former Chairman and new Lead Independent Director, Myron Kaplan. “His succession to Chairman strengthens CorMedix Therapeutics and best positions the company for future success.”","length":393,"tagName":"p"},{"type":"text","content":"CorMedix is also pleased to announce the appointment of Mr. Mike Seckler to the role of EVP & Chief Commercial Officer. Mr. Seckler joins CorMedix with a wealth of experience across multiple therapeutic areas including hematology and oncology, and most recently served as CEO of Evome Medical Technologies Inc. Mr. Seckler’s previous experience includes roles as COO of FerGene Inc., a Blackstone Life Sciences and Ferring Pharmaceuticals joint partnership gene therapy company, as well as head of Global Marketing and Corporate Communications for Ferring International.","length":574,"tagName":"p"},{"type":"text","content":"Joseph Todisco, CEO of CorMe...